<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.n338</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-338</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>Прогностическое значение способа определения расчетной скорости клубочковой фильтрации при декомпенсации хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка: акцент на цистатин С</article-title><trans-title-group xml:lang="en"><trans-title>The prognostic value of the method for determining the estimated glomerular filtration rate in chronic heart failure with a preserved left ventricular ejection fraction: focus on cystatin C</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никифорова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikiforova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"/><email xlink:type="simple">agishm@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щекочихин</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchekochikhin</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Trubetskaya st. 8-2, Moscow 119992</p></bio><email xlink:type="simple">agishm@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Манаа</surname><given-names>Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Manaa</surname><given-names>H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Trubetskaya st. 8-2, Moscow 119992</p></bio><email xlink:type="simple">dr.houssem@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ломоносова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lomonosova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"/><email xlink:type="simple">anastasia_los@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козловская</surname><given-names>Н. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlovskaya</surname><given-names>N. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>129327, Москва, ул. Ленская, 15</p></bio><bio xml:lang="en"/><email xlink:type="simple">nkozlovskaya@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Копылов</surname><given-names>Ф. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kopylov</surname><given-names>F. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"/><email xlink:type="simple">fjk@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сыркин</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Syrkin</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"/><email xlink:type="simple">previntenscardiology@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical Univesity</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «ГКБ им. А. К. Ерамишанцева» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital named after A.K. Yeramishantsev Department of Health of Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>09</month><year>2019</year></pub-date><volume>59</volume><issue>11S</issue><fpage>69</fpage><lpage>76</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/338">https://cardio.elpub.ru/jour/article/view/338</self-uri><abstract><p>Цель. Определение прогностического значения снижения расчетной скорости клубочковой фильтрации (рСКФ) согласно формуле CKD-EPI с учетом креатинина (Кр) крови и формулы, учитывающей одновременно Кр и цистатин С крови у пациентов, впервые госпитализированных в связи с декомпенсацией хронической сердечной недостаточности (ХСН) с сохраненной ФВ ЛЖ (СНсФВ), при наблюдении в течение 24 месяцев. Материалы и методы. В исследование включены 117 пациентов (женщин 65,8%, средний возраст 71,6±9,1 год), впервые госпитализированных с декомпенсацией ХСН и имеющих сохраненную ФВ ЛЖ. Исследование представляло собой проспективное наблюдение в течение 2-х лет после включения каждого пациента. В первые сутки госпитализации всем пациентам забирали пробы сывороток крови для определения уровня цистатина С. рСКФ определяли по формуле CKD-EPI с учетом уровня Кр крови и комбинированной формуле, включающей значения Кр и цистатина С. В качестве конечной точки (КТ) использовалась комбинация смерти от любой причины и повторной госпитализации в связи с декомпенсацией СН в течение двух лет наблюдения. Для определения влияния снижения рСКФ на прогноз использовалась методика Каплана–Майера и log-rank тест. Различия считали статистически значимыми при р&lt;0,05. Результаты. За время наблюдения смертность составила 11,9%. Повторно в связи с декомпенсацией СН госпитализировался каждый третий пациент (33,1%). С целью определения влияния снижения рСКФ на достижение КТ все пациенты были разделены на группы со значениями рСКФ более или менее 45 мл/мин/1,73 м2 согласно обеим формулам. При разделении пациентов с использованием формулы CKD-EPI, включающей только Кр крови, группы не различались как по частоте достижения комбинированной КТ, так и ее компонентов. Однако пациенты со значениями рСКФ менее 45 мл/мин/1,73 м2 по данным комбинированной формулы статистически значимо чаще достигали комбинированной КТ (p=0,03), преимущественно за счет увеличения смертности (p=0,03). Заключение. Полученные данные позволяют предположить, что добавление цистатина С к формуле CKD-EPI и выявление пациентов со сниженной рСКФ имеет высокую прогностическую ценность для стратификации риска неблагоприятного исхода после первой декомпенсации СНсФВ.</p></abstract><trans-abstract xml:lang="en"><p>The aim of the present study is to determine the prognostic value of GFR reduction according to the CKD-EPI formula, taking into account blood creatinine and a formula that simultaneously takes into account creatinine and cystatin C in patients who were hospitalized for the first time due to decompensation of chronic heart failure with a preserved left ventricular ejection fraction (HFSA) observation within 24 months. Materials and methods. The study included 117 patients (women – 65.8%, mean age 71.6 ± 9.1 years) hospitalized due to debugging of CHF and having a preserved left ventricular ejection fraction according to echocardiography. The study was a prospective observation for 2 years after the inclusion of each patient. On the first day of hospitalization, all serum samples were taken to determine the level of cystatin C. The estimated glomerular filtration rate (eGFR) was determined using the CKD-EPI formula, taking into account blood creatinine and the combined formula, including creatinine and cystatin C. The combination was used as an end point death and re-hospitalization within two years of follow-up. To determine the effect of a decrease in eGFR on the forecast, the Kaplan–Maer method and the log-rank test were used. Differences were considered statistically significant at p&lt;0.05. The study was approved by the local ethics committee. Results. During the observation period, the mortality rate was almost 12%. At the same time, every third patient was repeatedly hospitalized within two years. In order to determine the effect of reducing GFR on reaching the end points, all patients were divided into groups with eGFR values of more or less than 45 ml/min/1.73 sq.m according to both formulas. When separating patients using the CKD-EPI formula, which includes only creatinine, the groups did not differ in terms of the frequency of reaching the combined end point, as well as its components: death and re-hospitalization. However, patients with eGFR values less than 45 ml/min/1.73 sq. M according to the combined formula data significantly more often reached the combined end point, mainly due to an increase in mortality. Conclusion. The data obtained suggest that adding cystatin C to the CKD-EPI formula and appropriately identifying patients with reduced eGFR has a high prognostic value for stratifying the risk of an unfavorable outcome after the first decompensation of HFSSFV.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность с сохраненной фракцией выброса</kwd><kwd>цистатин С</kwd><kwd>кардиоренальный синдром</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Chronic heart failure with preserved ejection fraction</kwd><kwd>cystatin C</kwd><kwd>cardiorenal syndrome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Конфликт интересов отсутствует.</funding-statement><funding-statement xml:lang="en">no conflict of interest</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a communitybased cohort: 11-year follow-up of PREVEND. European Heart Journal. 2013;34(19):1424–31. DOI: 10.1093/eurheartj/eht066</mixed-citation><mixed-citation xml:lang="en">Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a communitybased cohort: 11-year follow-up of PREVEND. European Heart Journal. 2013;34(19):1424–31. DOI: 10.1093/eurheartj/eht066</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7(3):112-5.</mixed-citation><mixed-citation xml:lang="en">Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S. et al. Prevalence of chronic heart failure in European part of Russian Federation - Data of AGE-CHF (Part II). Russian Heart Failure Journal. 2006;7(3):112–5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006;355(3):251–9. DOI: 10.1056/NEJMoa052256</mixed-citation><mixed-citation xml:lang="en">Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006;355(3):251–9. DOI: 10.1056/NEJMoa052256</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХАО-ХСН: снова о проблеме ХСН с сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7(4):164- 71</mixed-citation><mixed-citation xml:lang="en">Mareev V.Yu., Danielyan M.O., Belenkov Yu.N. Comparative characteristics of patients with CHF in relation to the value of injection fraction by data from the Russian multicenter study EPOCH-A-CHF: once more about the problem of CHF with preserved left ventricular systolic function. Russian Heart Failure Journal. 2006;7(4):164–71.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Дикур О. Н., Полтавская М. Г., Гиверц И. Ю., Долецкий А. А., Пешева О.В., Сыркин А.Л. Желудочково-артериальное сопряжение при хронической сердечной недостаточности с сохраненной и сниженной фракцией выброса левого желудочка. Кардиология и сердечно-сосудистая хирургия. 2014;7(4):59–68</mixed-citation><mixed-citation xml:lang="en">Dikur O.N., Poltavskaia M.G., Giverts I.Yu., Doletskiy A.A., Pesheva O.V., Syrkin A.L. Ventricular-arterial coupling in case of chronic heart failure with preserved and reduced left ventricular ejection fraction. Cardiology and cardiovascular surgery. 2014;7(4):59–68.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Current Opinion in Nephrology and Hypertension. 2006;15(6):610–6. DOI: 10.1097/01.mnh.0000247505.71915.05</mixed-citation><mixed-citation xml:lang="en">Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Current Opinion in Nephrology and Hypertension. 2006;15(6):610–6. DOI: 10.1097/01.mnh.0000247505.71915.05</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine. 2012;367(1):20–9. DOI: 10.1056/NEJMoa1114248</mixed-citation><mixed-citation xml:lang="en">Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine. 2012;367(1):20–9. DOI: 10.1056/NEJMoa1114248</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–12. DOI: 10.7326/0003-4819-150-9-200905050-00006</mixed-citation><mixed-citation xml:lang="en">Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–12. DOI: 10.7326/0003-4819-150-9-200905050-00006</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine. 2006;355(3):260–9. DOI: 10.1056/NEJMoa051530</mixed-citation><mixed-citation xml:lang="en">Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine. 2006;355(3):260–9. DOI: 10.1056/NEJMoa051530</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lassus J, Harjola V-P, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. European Heart Journal. 2007;28(15):1841–7. DOI: 10.1093/eurheartj/ehl507</mixed-citation><mixed-citation xml:lang="en">Lassus J, Harjola V-P, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. European Heart Journal. 2007;28(15):1841–7. DOI: 10.1093/eurheartj/ehl507</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. Journal of the American College of Cardiology. 2006;47(10):1987–96. DOI: 10.1016/j.jacc.2005.11.084</mixed-citation><mixed-citation xml:lang="en">Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. Journal of the American College of Cardiology. 2006;47(10):1987–96. DOI: 10.1016/j.jacc.2005.11.084</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M et al. Cystatin C in Acute Heart Failure Without Advanced Renal Impairment. The American Journal of Medicine. 2009;122(6):566–73. DOI: 10.1016/j.amjmed.2008.10.042</mixed-citation><mixed-citation xml:lang="en">Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M et al. Cystatin C in Acute Heart Failure Without Advanced Renal Impairment. The American Journal of Medicine. 2009;122(6):566–73. DOI: 10.1016/j.amjmed.2008.10.042</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, MartínezMarcos FJ, Camacho-Vázquez C, Ruiz-Frutos C et al. Prognostic Value of Cystatin C on Admission in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. 2011;17(1):31–8. DOI: 10.1016/j.cardfail.2010.07.248</mixed-citation><mixed-citation xml:lang="en">Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, MartínezMarcos FJ, Camacho-Vázquez C, Ruiz-Frutos C et al. Prognostic Value of Cystatin C on Admission in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. 2011;17(1):31–8. DOI: 10.1016/j.cardfail.2010.07.248</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Huerta A, López B, Ravassa S, José GS, Querejeta R, Beloqui Ó et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. Journal of Hypertension. 2016;34(1):130–8. DOI: 10.1097/HJH.0000000000000757</mixed-citation><mixed-citation xml:lang="en">Huerta A, López B, Ravassa S, José GS, Querejeta R, Beloqui Ó et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. Journal of Hypertension. 2016;34(1):130–8. DOI: 10.1097/HJH.0000000000000757</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
